Srinagar Magazine

30+ Active Companies working to develop 30+ Pipeline Therapies for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment Landscape Analysis

 Breaking News
  • No posts were found

30+ Active Companies working to develop 30+ Pipeline Therapies for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment Landscape Analysis

April 06
14:12 2023
30+ Active Companies working to develop 30+ Pipeline Therapies for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment Landscape Analysis

DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2023” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging drugs, the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) clinical trials studies, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Report

 

  • DelveInsight’s EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment.

 

  • The leading EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Companies include Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others.

 

  • Promising EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapies include ZD9291 80 mg/40 mg, Erlotinib 150/100mg, Dacomitinib, TAK-788, Pemetrexed, Cisplatin, Carboplatin, Dacomitinib (PF-00299804), Gefitinib, D-0316 Capsule, Icotinib Hydrochloride Tablets, Chemotherapy, and others

 

  • The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Companies and academics that are working to assess challenges and seek opportunities that could influence EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) R&D. The EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline treatment landscape of the report, click here @ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Outlook

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Overview

Lung cancer is a type of cancer that starts in the lungs. Cancer starts when cells in the body begin to grow out of control. About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.

 

Recent Developmental Activities in the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment Landscape

 

  • In May, 2021, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

 

  • In May, 2021, the FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Rybrevant today.

 

  • On December 18, 2020, the Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

 

  • Novartis is conducting a phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies. This study will estimate the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (Phase l part) of EGF816 and to investigate the anti-tumor activity of EGF816 (Phase II part).

 

For further information, refer to the detailed EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Unmet Needs, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Latest Drugs Launch News, click here for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Ongoing Clinical Trial Analysis

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging Drugs Profile

 

  • DZD9008: Dizal Pharmaceuticals

DZD9008 is an oral, potent, irreversible, wild type-selective EGFR TKI against EGFR or HER2 Exon20ins and other mutations. The present study shows anti-tumor activity of DZD9008 in tumor cell lines and xenograft models. Dizal Pharmaceuticals is conducting a phase I/II, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics and anti-tumor efficacy of DZD9008 in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation. This study includes dose escalation (Part A) and dose expansion (Part B). This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.

 

  • Nazartinib (EGF816) – Novartis Pharmaceuticals

EGF816 is an orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGF816 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

 

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapeutics Assessment

There are approx. 30+ key companies which are developing the therapies for EGFR Non-Small Cell Lung Cancer. The companies which have their EGFR Non-Small Cell Lung Cancer drug candidates in the advanced stage, i.e. phase III and Phase II include, AstraZeneca, Betta Pharmaceuticals, Millennium Pharmaceuticals, Takeda etc.

 

Request a sample and discover the recent advances in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Ongoing Clinical Trial Analysis and Medications, click here @ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Treatment Landscape Analysis

 

Scope of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Report

 

  • Coverage- Global

 

  • EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Companies- Dizal Pharmaceuticals, Novartis Pharmaceuticals, AstraZeneca, Betta Pharmaceuticals Co., Ltd., Hangzhou ACEA Pharmaceutical Research, G1 Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Takeda, Janssen Research & Development LLC, Sinocelltech Ltd., Allist Pharmaceuticals, Inc., and others.

 

  • EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Therapies- ZD9291 80 mg/40 mg, Erlotinib 150/100mg, Dacomitinib, TAK-788, Pemetrexed, Cisplatin, Carboplatin, Dacomitinib (PF-00299804), Gefitinib, D-0316 Capsule, Icotinib Hydrochloride Tablets, Chemotherapy, and others.

 

  • EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Drivers and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Barriers, click here @ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. EGFR Non-Small Cell Lung Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. EGFR Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. EGFR Non-Small Cell Lung Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Mobocertinib (TAK 788): ARIAD Pharmaceuticals
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II/III)
  13. AZD3759: AstraZeneca
  14. Early Stage Products (Phase I/II)
  15. DZD9008: Dizal Pharmaceuticals
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. EGFRm inhibitors: HitGen
  19. Drug profiles in the detailed report…..
  20. Inactive Products
  21. EGFR Non-Small Cell Lung Cancer Key Companies
  22. EGFR Non-Small Cell Lung Cancer Key Products
  23. EGFR Non-Small Cell Lung Cancer- Unmet Needs
  24. EGFR Non-Small Cell Lung Cancer- Market Drivers and Barriers
  25. EGFR Non-Small Cell Lung Cancer- Future Perspectives and Conclusion
  26. EGFR Non-Small Cell Lung Cancer Analyst Views
  27. EGFR Non-Small Cell Lung Cancer Key Companies
  28. Appendix

 

Got Queries? Find out the related information on EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Mergers and acquisitions, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Licensing Activities @ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging Drugs, and Recent Trends

 

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/